Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
This article was originally published in The Pink Sheet Daily
Executive Summary
After additional cardiovascular events are seen, European regulators move to pull sibutramine, while FDA asks for a contraindication.
You may also be interested in...
Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase
FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.
Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase
FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.
Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety
SEOUL - Korea FDA banned new prescriptions for Abbott's obesity product sibutramine while it recommended "voluntary withdrawal" of the product following similar actions in the U.S. and Europe, drawing criticism that KFDA is too reliant on foreign agencies for monitoring drug safety